Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis.
diabetes mellitus type 2
idegasp
insulin
meta-analysis
systematic review
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
accepted:
02
06
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
Type 2 diabetes mellitus is a prevalent metabolic disease requiring tight glycemic control of basal and postprandial glucose levels. Treatment intensification using separate basal and bolus injections increased the number of injections and reduced cost-effectivity, leading to decreased compliance and failure of glycemic control. Insulin Degludec/Insulin Aspart (IDegAsp), a novel premix of basal and bolus insulin, is one of the potential treatments for reducing the number of injections. However, its efficacy and safety have not been reviewed clearly. Therefore, this systematic review aims to compare the efficacy and safety of IDegAsp with standard basal and basal plus bolus insulin regimens. A systematic review of four databases (Pubmed, Scopus, Science Direct, and Proquest) was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Search results were screened by eligibility criteria and critically appraised by the Oxford Centre for Evidence-Based Medicine (CEBM) tool and the Cochrane risk-of-bias
Identifiants
pubmed: 35784980
doi: 10.7759/cureus.25612
pmc: PMC9249063
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e25612Informations de copyright
Copyright © 2022, Edina et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Pharmacokinet. 2017 Apr;56(4):339-354
pubmed: 27696221
Diabetes Care. 2014 Aug;37(8):2084-90
pubmed: 24812432
Diabetes Res Clin Pract. 2019 Jan;147:157-165
pubmed: 30448451
Diabet Med. 2017 Feb;34(2):180-188
pubmed: 27027878
Diabet Med. 2016 Apr;33(4):497-505
pubmed: 26435365
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
J Diabetes. 2015 May;7(3):315-21
pubmed: 25195971
J Diabetes. 2017 Mar;9(3):243-247
pubmed: 27059529
J Assoc Physicians India. 2015 May;63(5 Suppl):15-20
pubmed: 26548030
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Endocr Pract. 2016 May;22(5):546-54
pubmed: 26720250
Diabetes Obes Metab. 2019 Jul;21(7):1652-1660
pubmed: 30869183
Diabetes Obes Metab. 2016 Mar;18(3):274-80
pubmed: 26592732
Diabetes Obes Metab. 2013 Sep;15(9):826-32
pubmed: 23557077
Diabetes Res Clin Pract. 2015 Jan;107(1):139-47
pubmed: 25498130
Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):542-5
pubmed: 27366723
Int J Clin Pract. 2016 Aug;70(8):657-67
pubmed: 27384031
Diabetes Ther. 2014 Jun;5(1):65-72
pubmed: 24828136
Endocrinol Metab (Seoul). 2019 Dec;34(4):382-389
pubmed: 31884738